Background {#Sec1}
==========

Botulinum toxin A (BTX), a toxin produced by *Clostridium botulinum*, binds to snail protein in the presynaptic cholinergic nerve and inhibits the acetylcholine release \[[@CR1]\]. As the neurotransmitter of the motor nerve is acetylcholine, BTX can be used for intentional skeletal muscle weakening \[[@CR2]\]. BTX can be used to decrease the hyperactivity of the masseter and the temporal muscles for reducing painful conditions \[[@CR2]\]. Myofascial pain is described as a muscle hyperactivity involving facial pain related to temporomandibular disorders \[[@CR3]\]. Tension headaches and neck pain are usually caused by masticatory muscle hyperactivity \[[@CR4]\]. Secretion of the salivary gland and sweat gland is also controlled by the cholinergic nerve \[[@CR5]\]. Accordingly, BTX has been widely used in the dental field. BTX is used for the treatment of temporomandibular disorders \[[@CR2]\], sialorrhea \[[@CR5]\], post-traumatic open bite \[[@CR6]\], and masseteric muscle hypertrophy \[[@CR7], [@CR8]\].

To achieve optimal results, optimal dosage of BTX injection should be important. For the treatment of the masseter muscle hypertrophy, 25 to 30 U of BTX has been generally given for each side \[[@CR7], [@CR9]\]. The maximum bite force is reduced after injection of BTX into the masseter muscle \[[@CR10]\]. Complications of BTX injection into the masseter muscle, such as a temporary change in the bite force, have been reported \[[@CR7], [@CR8]\].

There have been several reports to investigate the effect of BTX injection into the masseter muscle in the animal model \[[@CR11]--[@CR14]\]. The injection of BTX immediately reduces the masseter muscle activity measured by electromyogram \[[@CR12]\]. BTX changes the component of muscle fiber and morphology of the mandible at 1 month after injection \[[@CR13], [@CR14]\]. However, early changes of muscle fiber component have not been studied. Post-traumatic open bite is corrected within a couple of days after BTX injection \[[@CR6]\]. Some patients showed temporary muscle weakness immediately after BTX injection \[[@CR7], [@CR8]\]. Thus, early change after BTX injection on the masseter muscle is important to understand the clinical application of BTX.

The purpose of this study was to evaluate the change of food intake after different dosages of BTX injection in the animal model. Additionally, dimensional and histological change at 14 days after BTX injection was also evaluated.

Methods {#Sec2}
=======

Animals and experimental design {#Sec3}
-------------------------------

Male Wistar rats aged 18 weeks were purchased from Samtako (Seoul, Korea). They were housed individually in controlled temperature (20--22 °C) and hygrometry (around 40 %) in a 12-h light:12-h darkness cycle. They had free access to water. During the adaptation period (first week), all rats were fed ad libitum with a control semi-synthetic diet (4 % lipids from soya vegetal oil, 74 % carbohydrates from sucrose and cornstarch, and 14 % proteins from casein, supplemented with standard vitamins and mineral mix), following classical recommendations. All diets were prepared within Gangneung-Wonju National University facilities. All groups were maintained ad libitum for 7 days receiving a diet similar to the adaptation diet with measuring of daily spontaneous intake (26.1 ± 4.1 g/day, *n* = 15). At the end of the normal diet period, rats (20 weeks old) were separated: the control group received a saline injection into both masseter muscles (group 1, *n* = 5), and the others were separated in two groups for BTX injection study (*n* = 5 per group). These two groups were assessed in order to compare the dose-dependent effect of BTX injection on physiological parameters in two animal groups receiving re-feeding diets. All re-feeding diets were the same to the ad libitum control period. In order to measure food intake, all groups were individually housed. Group 1 was the saline-injected group. Group 2 was the 5-unit BTX-injection group to each masseter muscle. Group 3 was the 10-unit BTX-injection group to each masseter muscle. The recovery of food intake was measured until 10 days after the injection. All animals were sacrificed at 14 days after the injection for the histological analysis. All procedures were conducted according to the guidelines of laboratory animal care and were approved by the Gangneung-Wonju National University for animal research (GWNU-2015-24).

Histomorphometric evaluation {#Sec4}
----------------------------

The samples were harvested, decalcified in 5 % nitric acid for 5 days, and dehydrated in ethyl alcohol and xylene. After separation of the calvarial bones, the samples were embedded in paraffin blocks. The paraffin blocks were sliced into sections that were then stained with hematoxylin and eosin. The section with the occlusal plane area was selected.

The staining procedure for hematoxylin and eosin staining was as follows. First, de-wax and hydrate paraffin sections. The slide was stained in hematoxylin for 5 min. Overstained sections can easily be differentiated by agitating for a second in acid-alcohol then washing in tap water for 5 min. The slides were immersed in eosin for 30 s and then washed in running tap water for 1 min. The slides were dehydrated and cleared in xylene.

Digital images of the selected sections were captured with a digital camera (DP-73; Olympus, Tokyo, Japan). The images were analyzed by Sigma Scan pro (SPSS, Chicago, IL). The thickness of the masseter muscle was measured from the perpendicular line to the mandibular ramus.

Immunohistochemical determination of lysozyme and myosin type II in rat masseter muscle {#Sec5}
---------------------------------------------------------------------------------------

To determine the level of expression of myosin type II (MYH2), immunohistochemical staining was performed using anti-myosin type II antibodies (Santa Cruz Biotech, Santa Cruz, CA, USA). Paraffin-embedded tissues from rat masseter muscles were prepared. For antigen retrieval, sections were incubated in trypsin for 7 min at 37 °C. The primary antibody dilutions were as follows: MYH2, 1:50. The immunohistochemical procedures were performed as described in a previous publication \[[@CR15]\]. The negative controls were sections stained without primary antibodies.

Stained sections were examined in an Olympus BX51 (Olympus, Tokyo, Japan) microscope. To quantify the immunohistochemical reaction intensity, the positive intensity MYH2 staining in 10 random fields at ×200 magnification in the masseter muscle was evaluated by computer-assisted image analysis after image transformation to grayscale. The staining intensity was expressed as the mean intensity value (0, no stain; 255, highest stain). The samples were not counterstained so that the absorbance would be solely attributable to the product of the immunohistochemical reaction.

Statistical analysis {#Sec6}
--------------------

SPSS for Windows ver. 19 (IBM Co., Armonk, NY, USA) were used for statistical analysis. The differences among groups were evaluated by ANOVA. For post hoc tests, Bonferroni's method was used. The statistically significant level was set as *p* \< 0.05.

Results {#Sec7}
=======

There was no initial difference between the BTX and saline solution groups in any parameter, including body weight and the amount of food consumption during 24 h. Figure [1](#Fig1){ref-type="fig"} illustrates the relative amount of food consumption during the 24 h compared to before the injection. The relative amount of food intake in rats treated with BTX (5--10 U) decreased significantly compared with the saline group from day 2 to day 7 and day 9 after injection (*p* \< 0.05). In the post hoc test, both 5- and 10-U BTX treatments resulted in significantly lower values compared with the saline-treated control group from day 2 to day 6 (*p* \< 0.05). However, only the 10-U BTX treatment resulted in significantly lower values compared with the saline-treated control group at day 7 and day 9 (*p* = 0.031 and 0.049, respectively). There was no significant difference in body weight between the observation points (data not shown).Fig. 1The relative amount of food consumption during 24 h compared to before the injection. The recovery of food intake in rats treated with BTX (5--10 U) decreased significantly compared with the saline group from day 2 to day 7 and day 9 after injection (*asterisk*, *p* \< 0.05)

The BTX-treated masseter muscles were significantly smaller than the saline-solution-injected masseter muscles, as shown in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}. The thickness of the masseter muscle was 5.76 ± 1.28 mm, 4.66 ± 0.68 mm, and 3.65 ± 0.81 mm for the saline, 5-U, and 10-U BTX treatments, respectively (Fig. [2](#Fig2){ref-type="fig"}; *p* = 0.015). The post hoc test revealed differences between the group treated with 10 U BTX and the group treated with saline (control) resulting in significantly lower values (*p* = 0.013). In the histological view, the degenerative change of muscle fibers was prominent in the 10-U BTX-treated group. Inter-fiber spaces were lost in the 10-U BTX-treated group. Mild degenerative change was also noticed in the 5-U BTX-treated group (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2The thickness of the masseter muscle. The thickness of the masseter muscle in rats treated with BTX (5--10 U) was decreased significantly compared with the saline group at day 14 after injection (*asterisk*, *p* = 0.015) Fig. 3Histological view. **a** The saline-treated group, **b** 5-U BTX-treated group, **c** 10-U BTX-treated group. Interestingly, the thickness of the mandibular ramus (*asterisk*) was changed after BTX injection. Degenerative change was also shown in both the 5- and 10-U BTX-treated groups (hematoxylin and eosin stain, original magnification ×20)

The immunohistochemical findings demonstrated that the expression of MYH2 was much higher in the 10-U BTX-treated group compared to the saline group (Fig. [4](#Fig4){ref-type="fig"}). The mean intensity of MYH2 was 86.38 ± 8.66, 101.72 ± 12.41, and 144.51 ± 5.68 for the saline, 5-U, and 10-U BTX treatments, respectively (Fig. [4](#Fig4){ref-type="fig"}; *p* \< 0.001). The post hoc test revealed differences between the groups treated with 10 U BTX, resulting in significantly higher values compared with the saline-treated control and the 5-U BTX-treated group (*p* \< 0.001).Fig. 4Immunohistological view. **a** The saline-treated group, **b** 5-U BTX-treated group, **c** 10-U BTX-treated group. The immunohistochemical findings demonstrated that the expression of MYH2 was much higher in the 10-U BTX-treated group compared to the saline group (original magnification ×100 without counterstain)

Discussion {#Sec8}
==========

Recovery after BTX injection {#Sec9}
----------------------------

In this study, the recovery in food intake after BTX injection was taken approximately 10 days after injection (Fig. [1](#Fig1){ref-type="fig"}). When BTX is injected into the unilateral masseter muscle of an adult rabbit, the relative bite force is reduced over 85 % in 3 weeks after injection \[[@CR16]\]. Thus, 10 days might be a relatively fast recovery. After BTX injection of the unilateral masseter muscle, rabbits still masticate at the same rates and chew on both sides \[[@CR16]\]. At 12 weeks after unilateral injection, bite force has returned to pre-injection levels but the BTX-injected masseter muscle volume is still smaller than the contralateral muscle \[[@CR16]\]. This might have been due to the compensatory hyperfunction of the temporalis muscle to adjust to the masticatory function \[[@CR17]\]. In this study, the other masticatory muscles were intact except for the masseter muscle. Thus, early recovery of food intake rate might be due to the compensatory function of the other masticatory muscles.

The clinical literature indicates that maximal atrophy of the masseter of human is observed about 2 months after BTX injection and is sometimes persistent until 1 to 2 years \[[@CR18], [@CR19]\]. However, voluntary bite force is subjectively normal within 8 days after BTX injection in one report \[[@CR20]\]. Patients report only brief periods of problems with chewing after BTX injection and the return of normal function after a short time \[[@CR21]\]. Our results demonstrated similar results with previous publications (Fig. [1](#Fig1){ref-type="fig"}).

Muscle and bone changes after BTX injection {#Sec10}
-------------------------------------------

The dosage of BTX expected to cause muscle paralysis is 20--30 U for rodents \[[@CR22]\]; therefore, 5 and 10 U were used in this experiment. Injections of BTX decrease the force of masseter muscle contractions and decrease tension on the periosteum \[[@CR23]\]. The BTX-treated masseter muscles were significantly smaller than the saline-solution-injected masseter muscles, as shown in Fig. [2](#Fig2){ref-type="fig"}. The masseter muscle may be involved in maintaining mandibular bone volume through changes in bone metabolism \[[@CR22]\]. Accordingly, bony deposition decreases and a morphological change are induced \[[@CR24]\]. A reduced cortical bone thickness of the mandibular ramus in our study (Fig. [3](#Fig3){ref-type="fig"}) was also consistent with the research of previous publications \[[@CR25], [@CR26]\]. The diminished forces cause the remodeling process of bone growth, which circumferentially reduces the cortical bone thickness. When BTX is used on the limb muscle, bone loss is observed in the tibia and distal femur \[[@CR27], [@CR28]\].

MYH change after BTX injection {#Sec11}
------------------------------

MYH is found in all eukaryotic cells, where it provides the motor function \[[@CR29]\]. There are several types of MYH, and they can be classified by their contraction speed as fast type and slow type \[[@CR29]\]. MYH2 is fast type \[[@CR30]\]. Masticatory muscle fibers can adapt to stress by changing their myosin composition, and they are found after orthognathic surgery of patients with malocclusions \[[@CR31], [@CR32]\]. The patients having mandibular asymmetry are associated with a significant increase of MYH2 \[[@CR33]\]. In addition, MYH2 occupancy is increased in deep bites \[[@CR34]\].

It was shown that intramuscular BTX application induces direct and significant alterations of the fiber composition \[[@CR35]\]. Just like BTX injection, chronic denervation is followed by changes of the fiber type composition and MYH content in rat muscles \[[@CR36], [@CR37]\]. Endurance muscle training induced by sagittal advancement of the mandible induces an increase of MYH1 in pigs \[[@CR38]\]. MYH2 is increased in the masseter muscle after BTX injection \[[@CR39]\]. In our study, MYH2 was significantly increased in the masseter muscle after BTX injection and its increasing was BTX dose dependent (Fig. [4](#Fig4){ref-type="fig"}). Unlike BTX injection, sleep deprivation is associated with significantly decreased MYH2 in the masseter muscle in rats \[[@CR40]\]. Though our study indicated that BTX injection could increase MYH2 occupancy in the masseter muscle, because human masseter and temporal muscles have also heterogeneous fiber-type composition, the proportion of MYH2 being generally smaller \[[@CR41]\], there will be needed translational research in humans.

Conclusions {#Sec12}
===========

In conclusion, BTX injection to the masseter muscle in rats demonstrated a short food-intake-rate reduction with recovery until 10 days after injection. The thickness of the masseter muscle and MYH2 expression were significantly changed according to the injected dose of BTX.
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